17342-08-4Relevant articles and documents
INHIBITORS OF APOL1 AND METHODS OF USING SAME
-
, (2020/07/14)
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
Biphenyl compound as well as preparation method and medical application thereof
-
Paragraph 1517-1523, (2020/11/22)
The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.
5-HT7 Receptor Antagonists with an Unprecedented Selectivity Profile
Ates, Ali,Burssens, Pierre,Lorthioir, Olivier,Lo Brutto, Patrick,Dehon, Gwenael,Keyaerts, Jean,Coloretti, Francis,Lallemand, Bénédicte,Verbois, Valérie,Gillard, Michel,Vermeiren, Céline
, p. 795 - 802 (2018/04/02)
-